[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis",
    "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is one of them. Johnson & Johnson (NYSE:JNJ), a global healthcare leader, continues to strengthen its pharmaceuticals and immunology portfolio while delivering strong stock performance in 2025. This month, the company received […]",
    "url": "https://finnhub.io/api/news?id=a5f76184c324ff4443a6c17f9f2d51ceaea4296e4a285cb2da331eebbafadaac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758668521,
      "headline": "Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis",
      "id": 136858133,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is one of them. Johnson & Johnson (NYSE:JNJ), a global healthcare leader, continues to strengthen its pharmaceuticals and immunology portfolio while delivering strong stock performance in 2025. This month, the company received […]",
      "url": "https://finnhub.io/api/news?id=a5f76184c324ff4443a6c17f9f2d51ceaea4296e4a285cb2da331eebbafadaac"
    }
  },
  {
    "ts": null,
    "headline": "Tracking John Paulson's Paulson & Company Portfolio - Q2 2025 Update",
    "summary": "John Paulson's Paulson & Company 13F portfolio rose to ~$2.01B in Q2 2025. Check out the significant stake increases and new stakes in the portfolio.",
    "url": "https://finnhub.io/api/news?id=ecb7703b60633f97c48bb557e6d9dff98e5680c8395fe5c43ae2d71bc7082789",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758661384,
      "headline": "Tracking John Paulson's Paulson & Company Portfolio - Q2 2025 Update",
      "id": 136857386,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518840746/image_518840746.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "John Paulson's Paulson & Company 13F portfolio rose to ~$2.01B in Q2 2025. Check out the significant stake increases and new stakes in the portfolio.",
      "url": "https://finnhub.io/api/news?id=ecb7703b60633f97c48bb557e6d9dff98e5680c8395fe5c43ae2d71bc7082789"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue stock rebounds as Trump's Tylenol claims face pushback",
    "summary": "STORY: Shares of Tylenol-maker Kenvue rose as much as 7% Tuesday morning, rebounding from a record low after investors shrugged off unproven claims from U.S. President Donald Trump linking the popular pain reliever to autism.On Monday, Trump connected autism to the use of Tylenol—known generically as acetaminophen or paracetamol—by pregnant women, elevating claims that are not supported by scientific evidence.Ahead of his remarks, investors braced for potentially damaging news, driving Kenvue’s shares down roughly 7.5% to an all-time low.But as one analyst told Reuters, Trump presented “no new scientific evidence” linking Tylenol to autism.Many doctors also reject the claim, and Kenvue—spun off from Johnson & Johnson in 2023—reiterated that there is no scientific link between the drug and autism, warning that such suggestions could pose risks to maternal health.Health agencies in the European Union and the United Kingdom also confirmed the safety of paracetamol during pregnancy.The U.S. Food and Drug Administration said it will update labels on Tylenol and generic versions to reflect a possible link between the drug's use during pregnancy and neurological conditions such as autism. However, the agency emphasized that no causal relationship has been established.Tylenol generates roughly $1 billion in annual sales for Kenvue, according to brokerage Morningstar.",
    "url": "https://finnhub.io/api/news?id=7f349f8d2ebb3ea89cdca25f1450414b08b2e77b3094a8208653e3684e3cbef7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758650388,
      "headline": "Kenvue stock rebounds as Trump's Tylenol claims face pushback",
      "id": 136855510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "STORY: Shares of Tylenol-maker Kenvue rose as much as 7% Tuesday morning, rebounding from a record low after investors shrugged off unproven claims from U.S. President Donald Trump linking the popular pain reliever to autism.On Monday, Trump connected autism to the use of Tylenol—known generically as acetaminophen or paracetamol—by pregnant women, elevating claims that are not supported by scientific evidence.Ahead of his remarks, investors braced for potentially damaging news, driving Kenvue’s shares down roughly 7.5% to an all-time low.But as one analyst told Reuters, Trump presented “no new scientific evidence” linking Tylenol to autism.Many doctors also reject the claim, and Kenvue—spun off from Johnson & Johnson in 2023—reiterated that there is no scientific link between the drug and autism, warning that such suggestions could pose risks to maternal health.Health agencies in the European Union and the United Kingdom also confirmed the safety of paracetamol during pregnancy.The U.S. Food and Drug Administration said it will update labels on Tylenol and generic versions to reflect a possible link between the drug's use during pregnancy and neurological conditions such as autism. However, the agency emphasized that no causal relationship has been established.Tylenol generates roughly $1 billion in annual sales for Kenvue, according to brokerage Morningstar.",
      "url": "https://finnhub.io/api/news?id=7f349f8d2ebb3ea89cdca25f1450414b08b2e77b3094a8208653e3684e3cbef7"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Tuesday Afternoon",
    "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.2% and the Health Ca",
    "url": "https://finnhub.io/api/news?id=dd1362e8bb7cc4ade20e4781ecc3e08dcf671542f506e7ed6e02e9de0a5de871",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758649504,
      "headline": "Sector Update: Health Care Stocks Advance Tuesday Afternoon",
      "id": 136855511,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.2% and the Health Ca",
      "url": "https://finnhub.io/api/news?id=dd1362e8bb7cc4ade20e4781ecc3e08dcf671542f506e7ed6e02e9de0a5de871"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Upgrades Johnson & Johnson (JNJ)",
    "summary": "Guggenheim Upgrades Johnson & Johnson (JNJ)",
    "url": "https://finnhub.io/api/news?id=bddadc80199f05afc8d49e46bb56feee536f94f97f74ca91def274cee4bc3c8b",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758645027,
      "headline": "Guggenheim Upgrades Johnson & Johnson (JNJ)",
      "id": 136849976,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=bddadc80199f05afc8d49e46bb56feee536f94f97f74ca91def274cee4bc3c8b"
    }
  },
  {
    "ts": null,
    "headline": "Tesla, Lululemon, Johnson & Johnson: Top analyst calls",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks some of Wall Street's top analyst calls, including Tesla (TSLA), Lululemon (LULU), and Johnson & Johnson (JNJ). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=0f9bf45017a2c21ff208ce7aa32236315f912e896c90842e11b533a79f022737",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758641545,
      "headline": "Tesla, Lululemon, Johnson & Johnson: Top analyst calls",
      "id": 136850245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Brooke DiPalma tracks some of Wall Street's top analyst calls, including Tesla (TSLA), Lululemon (LULU), and Johnson & Johnson (JNJ). To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=0f9bf45017a2c21ff208ce7aa32236315f912e896c90842e11b533a79f022737"
    }
  },
  {
    "ts": null,
    "headline": "Trethera Receives $1.8 Million NIH Grant to Advance TRE-515 Development for Crohn’s Disease",
    "summary": "LOS ANGELES, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that the National Institutes of Health (NIH) awarded Trethera a $1.8 million grant for preclinical studies of TRE-515 as a Crohn’s disease treatment. Trethera’s lead drug candidate, TRE-515, is a once-daily oral therapy that inhibits deoxycytidine kinase (dCK), an enzyme critical to th",
    "url": "https://finnhub.io/api/news?id=a84771fce5b947493c15ae554133651a61c189011615a04de5522f0d801ed19c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758636420,
      "headline": "Trethera Receives $1.8 Million NIH Grant to Advance TRE-515 Development for Crohn’s Disease",
      "id": 136850401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "LOS ANGELES, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that the National Institutes of Health (NIH) awarded Trethera a $1.8 million grant for preclinical studies of TRE-515 as a Crohn’s disease treatment. Trethera’s lead drug candidate, TRE-515, is a once-daily oral therapy that inhibits deoxycytidine kinase (dCK), an enzyme critical to th",
      "url": "https://finnhub.io/api/news?id=a84771fce5b947493c15ae554133651a61c189011615a04de5522f0d801ed19c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson, Boston Scientific to Headline MEDevice Boston 2025 Keynote Sessions",
    "summary": "BOSTON, MA / ACCESS Newswire / September 23, 2025 / MEDevice Boston , the premier MedTech event connecting top OEMs (Original Equipment Manufacturers) with emerging suppliers and strategic partners, has announced its lineup of distinguished keynote ...",
    "url": "https://finnhub.io/api/news?id=9b8ebb4cc3677d20360b87342c05c1c433361ad4284ebb3c1fc05cc12b85d2cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758636000,
      "headline": "Johnson & Johnson, Boston Scientific to Headline MEDevice Boston 2025 Keynote Sessions",
      "id": 136850402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BOSTON, MA / ACCESS Newswire / September 23, 2025 / MEDevice Boston , the premier MedTech event connecting top OEMs (Original Equipment Manufacturers) with emerging suppliers and strategic partners, has announced its lineup of distinguished keynote ...",
      "url": "https://finnhub.io/api/news?id=9b8ebb4cc3677d20360b87342c05c1c433361ad4284ebb3c1fc05cc12b85d2cf"
    }
  },
  {
    "ts": null,
    "headline": "CoreWeave upgraded, Lululemon downgraded: Wall Street's top analyst calls",
    "summary": "CoreWeave upgraded, Lululemon downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=8ae115d5e4924672be3a769d3fdb07099f98981265fca402fa41324baa1887a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758634846,
      "headline": "CoreWeave upgraded, Lululemon downgraded: Wall Street's top analyst calls",
      "id": 136850403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "CoreWeave upgraded, Lululemon downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=8ae115d5e4924672be3a769d3fdb07099f98981265fca402fa41324baa1887a8"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s push into new medicines to offset the Stelara loss, Guggenheim says",
    "summary": "Investing.com -- Johnson & Johnson’s push into new medicines has helped it offset the loss of revenue from its blockbuster Stelara treatment, according to Guggenheim which upgraded the stock to Buy. The brokerage raised its target price to $206 from $167, citing confidence in the company’s lineup of treatments across oncology, immunology and neuroscience. “We are impressed by the top-line growth JNJ has delivered so far in FY 2025, despite the loss of market exclusivity for their $10Bn+ asset, S",
    "url": "https://finnhub.io/api/news?id=855db584b87dec0cf84c7218de210d87bb684d0a4e85c7f08d7db94f314f7619",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758632779,
      "headline": "J&J’s push into new medicines to offset the Stelara loss, Guggenheim says",
      "id": 136850404,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- Johnson & Johnson’s push into new medicines has helped it offset the loss of revenue from its blockbuster Stelara treatment, according to Guggenheim which upgraded the stock to Buy. The brokerage raised its target price to $206 from $167, citing confidence in the company’s lineup of treatments across oncology, immunology and neuroscience. “We are impressed by the top-line growth JNJ has delivered so far in FY 2025, despite the loss of market exclusivity for their $10Bn+ asset, S",
      "url": "https://finnhub.io/api/news?id=855db584b87dec0cf84c7218de210d87bb684d0a4e85c7f08d7db94f314f7619"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia Exposes a Stock Market Problem. How the Fed Can Solve It.",
    "summary": "Nvidia strikes another deal, Miran believes Fed rate is way too high, Disney restores Jimmy Kimmel’s show, and more news to start your day.",
    "url": "https://finnhub.io/api/news?id=d6ff3f0bbc918d41105a65bceb43ead08346dbafe88f4013e07a364409b6622f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758624420,
      "headline": "Nvidia Exposes a Stock Market Problem. How the Fed Can Solve It.",
      "id": 136850405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Nvidia strikes another deal, Miran believes Fed rate is way too high, Disney restores Jimmy Kimmel’s show, and more news to start your day.",
      "url": "https://finnhub.io/api/news?id=d6ff3f0bbc918d41105a65bceb43ead08346dbafe88f4013e07a364409b6622f"
    }
  },
  {
    "ts": null,
    "headline": "Tylenol-Maker’s Shares Sink amid Autism Scrutiny",
    "summary": "Studies exploring whether there’s a connection between Tylenol’s key ingredient acetaminophen and autism have had mixed results.",
    "url": "https://finnhub.io/api/news?id=2bb8a0e02ab2c900a26df4582c22eaeaec2d93c312a3799df67415fdfe4357f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758623400,
      "headline": "Tylenol-Maker’s Shares Sink amid Autism Scrutiny",
      "id": 136855512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Studies exploring whether there’s a connection between Tylenol’s key ingredient acetaminophen and autism have had mixed results.",
      "url": "https://finnhub.io/api/news?id=2bb8a0e02ab2c900a26df4582c22eaeaec2d93c312a3799df67415fdfe4357f6"
    }
  },
  {
    "ts": null,
    "headline": "The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now",
    "summary": "This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety?",
    "url": "https://finnhub.io/api/news?id=07af028eaf2964b65d3fc77e864e7c0e8cfbe733a628d5be86c69c76f0a18240",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758614700,
      "headline": "The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now",
      "id": 136850406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety?",
      "url": "https://finnhub.io/api/news?id=07af028eaf2964b65d3fc77e864e7c0e8cfbe733a628d5be86c69c76f0a18240"
    }
  }
]